anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses nutritional health porridge. The porridge comprises the following components: 18 to 30 parts of yam by weight, 18 to 30 parts of pearl barley by weight, 7 to 15 parts of gordon euryale seed by weight, 10 to 15 parts of adzuki bean by weight, 6 to 10 parts of red date by weight, 0.2 to 0.8 part of salt by weight and 13 to 16 parts of white granulated sugar by weight. The nutritional health porridge of the invention is made of the yam, the pearl barley, the gordon euryale seed, the adzuki bean and the red date, not only does not require too much energy expenditure of spleen and stomach, but also has rich nutrient which can supply vital energyand blood quickly. The invention makes full use of the yam and pearl barley, in addition, the adzuki bean and the red date are added, and the formula fully embodies the Medicinal and Edible thinking of Chinese medicines. The nutritional health porridge can strengthen the spleen and stomach, benefit the lung and kidney and enrich the vital energy and the blood, and the immunity can be enhanced and the occurrence of tumor can be effectively reduced by taking the porridge for a long time. The nutritional health porridge has rich nutrient and sweet palatability, and can be taken for a long term. The nutritional health porridge is suitable for general population, in particular for the people having spleen deficiency and frail body and people in the cancer treatment period as well as the convalescence period.
Many studies have demonstrated that Iron is essential for the metabolism, cell cycle regulation and metastasis in different cancer cell lines. It is also believed that Iron concentration will increase in cancer cells by enhancing expression of TFR-1 receptors and in case of receptor saturation, non-receptor-mediated pinocytosis would be a significant pathway for more iron intake. Iron deficiency may lead to increase P 53 which consequently will stop cell mitosis in G1-S state. It also increases expression of N-myc down-regulated gene 1 which can suppress metastasis in cancer. It has been suggested that Iron chelators may decrease leukemic tumor growth in animal models of acute myeloid leukemia (AML). Some other case studies demonstrated the role of Iron chelators in relapse and/or refractory AML. Finally a phase 1 clinical study is undertaken for evaluate the role of Tiapine and cytarabine for adult AML and high-risk myelodysplastic syndrome. So in this study the investigators try to evaluate the role of iron chelating agent (deferasirox) for patients with acute lymphatic leukemia (ALL) and AML patients who cannot be treated with standard chemotherapy regimes .
FIELD: medicine. SUBSTANCE: method involves carrying out X-ray endovascular occlusion of inconsistent left ovarian vein. Gianturco spiral is built-in into its lumen to make occlusion. Delivery catheter is rotated about its axis concurrently with spiral implantation giving compact form to the spiral to be implanted. Sclerosing agent solution is introduced into the vein lumen for making its occlusion and contrast union structure is formed with small quantity of contrasting agent introduced for forming the union. Next portion of the sclerosing agent is pushed out from catheter lumen when pulling catheter. EFFECT: enhanced effectiveness of treatment. 4 cl, 5 dwg
Vaccines for protecting pigs against paratyphoid (Salmonella choleraesuis) infection comprise the strain of Salmonella choleraesuis having the A.T.C.C. number 15478 or 15479, with a pharmaceutically acceptable diluent.  The composition is preferably an injectable unit dose, containing 108 to 109 viable bacteria, suitably being in 1 ml. of sterile distilled water.  An oral composition is also mentioned.  The strain A.T.C.C. 15478 is prepared by subculturing a culture of fully virulent microorganisms, from the organs of a pig which has died from paratyphoid, in eleven successive broth cultures, followed by plating out on nutrient agar, visually selecting a rough colony, and so plating out and selecting a further five times, the final culture being the deposited organisms.  Strain 15479 is prepared by treating a plate culture of virulent bacteria, from a broth culture obtained from a paratyphoid-infected pig, to treatment with Salmonella anti-o phage No. 1, at 37 DEG  C. for 24 hours, when complete lysis occurs, except for a few colonies.  One of these rough colonies is plated out five times as before to give a final culture of stable organisms of the deposited strain.  The bacteria may be freeze dried in ten volumes of Mist. dessicans for storage, and the lyophilisate suspended in sterile distilled water as required to give an injectable vaccine.  Alternatively, a 24-hour culture in nutrient broth may provide a vaccine directly. The invention also relates to the freeze dried cultures per se, and to a process for combatting paratyphoid in pigs.
System in which patient data from disposables are transmitted to a central diagnostic center. Disposables (1) carry an individual coding key for encoding patient data in a patient station (2). The disposable data is then sent over a data network to the diagnosis receiver station (3), while at the same time a code for the patient station and a disposable ID is sent in an unencoded format. The receiver station (3) is connected over a secure network with the disposable producer (7) in order to request a key corresponding to the disposable ID, so that the data can be decoded. Examples of disposables are bio-chips such as sensor chips that are used to analyze a patient blood drop, medicines that include details of tablets, etc. Data from any of these are sent to a central station so that patient data can be used to make a diagnosis or medicine details can be checked to see what a patient has taken. The disposable manufacturer assigns each disposable ID and retains a key for that ID that is requested by the central station at a later data when it receives that particular disposable.
Bleach protection agents and a bleaching pre-treatment method are disclosed. The bleach protection agents comprise an aqueous mixture comprising hydrolyzed keratin and a silane crosslinking agent. Pre-treated hair is dried to deposit a protective keratin-based film on the surface of the hair. Thereafter, a bleaching composition is applied to the protected hair. Upon exposure to the bleaching composition, the keratin-based film is sacrificed, the hair is bleached, and damage to the hair from the bleaching composition is minimized or avoided. Surprisingly, bleaching of the underlying hair is effectively accomplished while also preserving its elasticity, strength, smoothness, and overall quality.
CELEBREX has demonstrated significant reduction in joint tenderness/pain and joint swelling compared to placebo. CELEBREX was evaluated for treatment of the signs and symptoms of RA in placebo- and active-controlled clinical trials of up to 24 weeks in duration. CELEBREX was shown to be superior to placebo in these studies, using the ACR20 Responder Index, a composite of clinical, laboratory, and functional measures in RA. CELEBREX doses of 100 mg twice daily and 200 mg twice daily were similar in effectiveness and both were comparable to naproxen 500 mg twice daily.

Although CELEBREX 100 mg twice daily and 200 mg twice daily provided similar overall effectiveness, some patients derived additional benefit from the 200 mg twice daily dose. Doses of 400 mg twice daily provided no additional benefit above that seen with 100 mg to 200 mg twice daily.
Carteolol has not been detected in plasma following ocular instillation. However, as with other topically applied ophthalmic preparations, Carteolol may be absorbed systemically. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported with topical application of beta-adrenergic blocking agents (see CONTRAINDICATIONS).

Cardiac Failure: Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe failure.

In Patients Without a History of Cardiac Failure: Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of cardiac failure, Carteolol Hydrochloride should be discontinued.

Non-Allergic Bronchospasm: In patients with non-allergic bronchospasm or with a history of non-allergic bronchospasm (e.g., chronic bronchitis, emphysema), Carteolol Hydrochloride Ophthalmic Solution should be administered with caution since it may block bronchodilation produced by endogenous and exogenous catecholamine stimulation of beta2 receptors.

Major Surgery: The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial. Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures. Some patients receiving beta-adrenergic receptor blocking agents have been subject to protracted severe hypotension during anesthesia. For these reasons, in patients undergoing elective surgery, gradual withdrawal of beta-adrenergic receptor blocking agents may be appropriate.

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of such agonists as isoproterenol, dopamine, dobutamine or levarterenol (see OVERDOSAGE).

Diabetes Mellitus: Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute hypoglycemia.

Thyrotoxicosis: Beta-adrenergic blocking agents may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents which might precipitate a thyroid storm.
It is stated that Hashimoto's Thyroiditis (HT) is a risk factor for the development of Papillary Thyroid Cancer (PTC). However, the effect of HT on the coexistence of HT and PTC is still controversial. In this study, our aim is to investigate the effect of the presence of HT on clinicopathological data in patients with PTC. All 356 patients whose pathology was reported as PTC who were operated between 2015 and 2023 were included in the study. PTC patients were divided into 2 groups as those with and without HT. The effect of HT association on clinicopathological features was investigated. In 356 PTC patients, the rate of HT was 31.2%. PTC patients with HT had less multifocality (p < 0.05), more lymph node metastases (LNM) (p < 0.01) compared to PTC patients without HT. The presence of HT did not affect the bilaterality of the tumor, tumor diameter, lymphovascular invasion, or capsule invasion. While multifocality was observed less frequently in PTC patients with HT, lymph node metastasis rates were higher.
In genomic medicine, the concept of genetically transitional disease (GTD) refers to cases in which gene mutation is necessary but not sufficient to cause disease. In this Perspective, we apply this novel concept to rheumatic diseases, which have been linked to hundreds of genetic variants via association studies. These variants are in the 'grey zone' between monogenic variants with large effect sizes and common susceptibility alleles with small effect sizes. Among genes associated with rare autoinflammatory diseases, many low-frequency and/or low-penetrance variants are known to increase susceptibility to systemic inflammation. In autoimmune diseases, hundreds of HLA and non-HLA genetic variants have been revealed to be modest- to moderate-risk alleles. These diseases can be reclassified as GTDs. The same concept could apply to many other human diseases. GTD could improve the reporting of genetic testing results, diagnostic yields, genetic counselling and selection of therapy, as well as facilitating research using a novel approach to human genetic diseases.
GC012F will be infused at a dose of1- 3 x 10\^5 CAR+ T cells/kg after receiving lymphodepleting chemotherapy. Lenalidomide maintenance therapy will be given post month 6 at physicians' choice.
FIELD: medicine. SUBSTANCE: the present innovation deals with obtaining active substances, CNSS peptides, in particular, obtained out of raw material of animal origin with antiandrogenic and antiestrogenic activity. Lumbosacral department of spinal cord should be homogenized in sodium chloride solution at 1:10, 1:15 ratios, extract should be extracted twice, saturated with ammonium sulfate and centrifuged by stages for 25-30 min at 6000- 9000: during the first stage the residue should be removed, and during the second stage it should be dissolved in 0.8-1% in sodium chloride solution, salted out followed by chromatography in UV- spectrum within 220-280 nm to lyophilize a target product. The economy-type method is ecologically safe being of low labor intensity, it shortens terms for extracting and obtaining the residue and enables to obtain active peptides of high purity. EFFECT: higher efficiency. 3 ex, 2 tbl
<P>PROBLEM TO BE SOLVED: To improve convenience when inspection data related to a specimen are captured into a server.  <P>SOLUTION: An inspection data capturing apparatus 70 acquires inspection data from an analyzer 80 via a communication network N2. Then, the inspection data capturing apparatus 70 acquires a patient ID based on an operation signal by user operation from an operation unit. Then, the inspection data capturing apparatus 70 transmits an acquisition request for patient attribute information with the patient ID as a retrieval condition to a medical image server 40, an inspection data management server 60, an electronic medical chart server 30 and the like. Then, the inspection data capturing apparatus 70 acquires patient attribute information matching the retrieval condition. The inspection data capturing apparatus 70 adds the acquired patient attribute information as an identifier to the inspection data. The inspection data capturing apparatus 70 transmits (outputs) the inspection data as HL7-compliant specimen inspection result data to the inspection data management server 60.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Acyclovir ointment, USP is a synthetic nucleoside analogue active against herpes viruses. Acyclovir ointment 5% is a formulation for topical administration. Each gram of acyclovir ointment 5% contains 50 mg of acyclovir in a polyethylene glycol (PEG) base.

Acyclovir, USP is a white to off-white, crystalline powder with the molecular formula C8H11N5O3 and a molecular weight of 225. The maximum solubility in water at 37°C is 2.5 mg/mL. The pka’s of acyclovir are 2.27 and 9.25. The chemical name of acyclovir is 9-[(2-Hydroxyethoxy)methyl]guanine; it has the following structural formula:
BACKGROUND: Clean intermittent self-catheterisation (CISC or ISC) is used by patients/carers to empty the bladder if needed. Sometimes the urethral lumen leading out of the bladder is blocked; sometimes, the bladder (detrusor) muscle itself or the autonomic motor nerves innervating the bladder are damaged, resulting in a failure of the detrusor muscle to work, leading to a failure of the bladder being able to empty adequately. Prior consensus as to the indications and timing of CISC has yet to be provided. This article aims to provide a multidisciplinary consensus view on this subject.
CONCLUSION: It is evident that every patient needs to be considered individually, bearing in mind the symptoms and investigations to be considered. We emphasise the importance of considering the term Bladder Voiding Efficiency (BVE). One group of patients who might find CISC helpful are those with a neurological disorder; these include spinal injury patients, multiple sclerosis, Parkinson's, and a condition called cauda equina. Sometimes bladder problems are treated with anticholinergics, and others may be treated with Botox. These may cause the bladder not to empty at all, which is good for leaks but needs self-catheterisation to empty the bladder. In the past, hospitals used a permanent catheter called an 'indwelling' or a 'suprapubic' catheter. These can have side effects, including infections, stones, and pain. For CISC, disposable catheters are the best option for patients as they come in different sizes and styles to provide individualised care. In conclusion, we would like hospitals to consider each patient separately and not use a general 'one-size-fits-all' bladder function for these patients.
BACKGROUND: Cell energy metabolism controls the activation and function of dendritic cells (DCs). Inflammatory dendritic epidermal cells (IDECs) in skin lesions of atopic dermatitis (AD) express high-affinity IgE receptor (FcϵRI) and toll-like receptor 2 (TLR2), which mediate the generation and maintenance of inflammation. However, cellular energy metabolism and effector function of IDECs mediated by FcϵRI and TLR2 have not been fully elucidated.
METHODS: IDECs in vitro were treated with TLR2 agonist Pam3CSK4 and anti-IgE alone or in combination for 24 h. Further, we analyzed the expression of cell surface activation markers, production of inflammatory factors, and cellular energy metabolism profiles of IDECs by using flow cytometry, multiplex assay, RNA sequencing, targeted energy metabolism, and seahorse assays.
RESULTS: Compared to the unstimulated or anti-IgE groups, Pam3CSK4 alone or combined with anti-IgE groups significantly increased the expression of CD80, CD83, and CD86 on IDECs, but did not affect the expression of the above markers in the anti-IgE group. The release of inflammatory cytokines increased in the Pam3CSK4 alone or combined with anti-IgE groups, while there was a weak increasing trend in the anti-IgE group. The glycolysis/gluconeogenesis pathway of carbon metabolism was affected in all treatment groups. Furthermore, compared to the control group, we found a decrease in pyruvic acid, upregulation of PFKM, downregulation of FBP1, and increase in extracellular lactate, glycolysis rate, and glycolysis capacity after all treatments, while there was no difference between each treatment group. However, there was no difference in glycolytic reserve and mitochondrial basic and maximum respiration among all groups.
CONCLUSION: Our results indicate that glycolysis of IDECs may be activated through FcϵRI and TLR2 to upregulate inflammatory factors, suggesting that danger signals from bacteria or allergens might evoke an inflammatory response from AD through the glycolysis pathway.
Placebo (normal saline) one treatment injected into bilateral Crow's Feet Line areas on Day 1 and subsequent treatments if applicable until day 180. Botulinum toxin Type A (24U) injected into bilateral Crow's Feet Line areas at any additional treatments from day 180 onward. Based on retreatment criteria participants were eligible for up to 5 treatment cycles (2 Placebo + 3 botulinum toxin type A).
Treatment sequence 1 consisted of three dosing periods in which patients received single oral doses of placebo, 250 mg, and 500 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
The invention provides an electrified removed-foreign-matter separation, collection and releasing device. The device comprises a connection rod. The upper end of the connection rod is provided with a concentrating flux plate. A shell is arranged above the concentrating flux plate. The side wall of the shell is provided with a motor and a storage battery. A remote control chip is arranged on the storage battery. The motor is connected with the storage battery. An output shaft of the motor is connected with one end of a rotating shaft, the other end of the rotating shaft is arranged on the shell through a bearing, a containing box is fixedly arranged in the shell, a connection rope is wound on the rotating shaft, one end of the connection rope is fixed in the containing box, the other end of the connection rope is provided with a balancing weight, and an electromagnet is arranged on the containing box and is connected with the storage battery. The electrified removed-foreign separation, collection and releasing device has the advantages that an aircraft of a unmanned aerial vehicle is separated form the shell for bearing a mechanical arm, combination and separation of the aircraft and the mechanical arm are controlled by the electromagnet and the concentrating flux plate, working staff on the ground can pull the foreign matter to the ground through the connection rope by releasing and collecting the connection rope, and thus the foreign matter hung on wires is eliminated.
Different tests are used to evaluate the aerobic capacity of a person. This study aims to investigate the gender and Body Mass Index (BMI) difference in aerobic capacity measured by using shuttle and Spartacus test. The study was conducted on 230 high school students (135 girls and 95 boys) followed their study in public establishment in kenitra city (Morocco). All participants were classified according to their gender (male vs. female) and their BMI (normal weight vs. overweight-obese) and performed the both test of shuttle and Spartacus. Running speed at the last completed stage, run time, maximum heart rate (max HR) max HR and perceived exertion were measured and analyzed. For each test, VO2max was estimated by using the proposed equation. There was significant BMI difference in the measured parameters (p<0.001). Difference in VO2max between male and female remained significant with high-speed level in boys. A significant difference between males and females (p < 0.001) was observed in shuttle test. Participants with normal weight or physical activity had good aerobic capacity. Compared to the Shuttle test, the Spartacus provides a 11.5% higher final speed (11.2 vs. 9.7km/h) and a total test time 2.3 times longer (11.3vs. 4.9 min) (p < 0.001). Our study underlines the interest of the Spartacus test and is preliminary. Indeed, these results must now be replicated in a larger sample of obese adolescents.